Education
About Us
Working with TipRanks
Follow Us
Mind Medicine (MNMD)
NASDAQ:MNMD
MNMD Stock Chart & Stats
$12.35
-$0.97(-11.96%)
At close: 4:00 PM EST
$12.35
-$0.97(-11.96%)
Day’s Range― - ―
52-Week Range$4.70 - $14.43
Previous CloseN/A
Volume779.86K
Average Volume (3M)1.78M
Market Cap
$1.22B
Enterprise Value$843.91M
Total Cash (Recent Filing)$209.07M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Mar 05, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding98,509,280
10 Day Avg. Volume1,240,706
30 Day Avg. Volume1,782,510
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.03
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.17
Forecast
1Y Price Target
$28.25Price Target Upside128.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Emerge Phase 3 trial for MM120 in major depressive disorder is enrolling faster than initially expected.
Financial PositionMindMed secured $259M in financing, ensuring funding into 2028, which supports the completion of key programs.
Market PotentialMindMed remains significantly undervalued as key Phase 3 data readouts for generalized anxiety disorder and major depressive disorder present great unmet need and significant market opportunity.
Bears Say
Mind Medicine News
MNMD FAQ
What was Mind Medicine’s price range in the past 12 months?
Mind Medicine lowest stock price was $4.70 and its highest was $14.43 in the past 12 months.
What is Mind Medicine’s market cap?
Mind Medicine’s market cap is $1.22B.
When is Mind Medicine’s upcoming earnings report date?
Mind Medicine’s upcoming earnings report date is Mar 05, 2026 which is in 89 days.
How were Mind Medicine’s earnings last quarter?
Mind Medicine released its earnings results on Nov 06, 2025. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.501 by -$0.279.
Is Mind Medicine overvalued?
According to Wall Street analysts Mind Medicine’s price is currently Undervalued.
Does Mind Medicine pay dividends?
Mind Medicine does not currently pay dividends.
What is Mind Medicine’s EPS estimate?
Mind Medicine’s EPS estimate is -0.51.
How many shares outstanding does Mind Medicine have?
Mind Medicine has 98,509,280 shares outstanding.
What happened to Mind Medicine’s price movement after its last earnings report?
Mind Medicine reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.501. Following the earnings report the stock price went up 3.175%.
Which hedge fund is a major shareholder of Mind Medicine?
Currently, no hedge funds are holding shares in MNMD
Mind Medicine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.25 (128.74% Upside)
$28.25 (128.74% Upside)
Blogger Sentiment
Bullish
MNMD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.17%
12-Months-Change
Fundamentals
Return on Equity
-85.59%
Trailing 12-Months
Asset Growth
-25.91%
Trailing 12-Months
Company Description
Mind Medicine
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
MNMD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a largely positive outlook for Mind Medicine (MindMed) Inc., with significant achievements in clinical trial progress, financial strengthening through capital raise, and promising advancements in their pipeline. However, increased expenses and net loss reflect some financial challenges.View all MNMD earnings summariesMNMD Stock 12 Month Forecast
Average Price Target
$28.25
▲(128.74% Upside)
Technical Analysis
AnaptysBio
―
Enliven Therapeutics
―
Tyra Bioscience
―
Biohaven Ltd.
―
Inhibrx Biosciences Inc
―
Ownership Overview
1.72% Insiders
4.15% Mutual Funds
0.64% Other Institutional Investors
87.24% Public Companies and Individual Investors